This episode continues the discussion regarding the rapid evolution of mRNA technologies since COVID-19. Guests discuss the improvements that have occurred within just a few years, which are making these therapies more reliable, cost-effective and viable for personalized cancer, rare disease chronic disease treatment.Today’s episode is sponsored by Eclipsebio. From AI-ready datasets to sequencing validation, they drive RNA success.Explore their solutions at <a href="https://eclipsebio.com/" rel="ugc noopener noreferrer" target="_blank">⁠https://eclipsebio.com/⁠</a>. Host<a href="https://www.linkedin.com/in/lorielliskatz/" rel="ugc noopener noreferrer" target="_blank">⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠</a>, Head of Insights, BioSpace Guests<a href="https://www.linkedin.com/in/andy-geall-116a9624/" rel="ugc noopener noreferrer" target="_blank">⁠Andy Geall⁠</a>, Co-founder and Chief Development Officer, Replicate Bioscience; Chair of the Board, Alliance for mRNA Medicines<a href="https://www.linkedin.com/in/pad-chivukula-1905081/" rel="ugc noopener noreferrer" target="_blank">⁠Pad Chivukula⁠</a>, Co-founder, CSO &amp; COO, Arcturus Therapeutics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Sarepta’s Wild Week, CDER’s New Leader, FDA Rejections, Manufacturing Billions

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.